Ohtuvayre (Ensifentrine) - Ensifentine is effective in key patient subgroup: boost trial

Ohtuvayre (Ensifentrine) - Ensifentine, an inhaled therapy approved in the U.S. earlier this year for adults with chronic obstructive pulmonary disease (COPD), has been found to be safe and effective in improving clinical symptoms in patients with COPD, regardless of disease severity, smoking history and history of chronic bronchitis. Chronic bronchitis is a common form of chronic obstructive pulmonary disease characterized by inflammation of the lungs, increased mucus production, and a cough with mucus production for two consecutive years.

These results come from several post hoc analyzes of pooled data from the phase 3 augmentation clinical trials that support Ohtuvayre's U.S. approval in June 2024 as an inhaled maintenance therapy for COPD. A post hoc analysis is an analysis planned and completed after the trial has concluded. Since the FDA approved Ohtuvayre, we have seen a lot of interest from doctors prescribing it to patients with ongoing symptoms of COPD.

Regardless ofthe severity of COPD, smoking history, or presence of chronic bronchitis, Ohtuvayre has the potential to improve lung function, relieve symptoms, reduce exacerbation rates, and improve overall quality of life. These advantages are supported by Phase 3 enhanced data analysis recently demonstrated at CHEST 2024. New analysis shows Ohtuvaryre dilates airways, reduces inflammation

COPD is a chronic lung disease characterized by progressive airway inflammation and airway narrowing or obstruction. Ohtuvaryre relieves inflammation and promotes the clearance of mucus from the lungs by inhibiting the activity of two enzymes called phosphodiesterase 3 and phosphodiesterase 4 that simultaneously widen the airways (called bronchiectasis).

Together, the ENHANCE-1 (NCT04535986) and ENHANCE-2 (NCT04542057) trials enrolled more than 1,500 current or former adult smokers with moderate to severe COPD. Participants were randomly assigned to take Ohtuvayre (3 mg) or a placebo via a nebulizer twice daily for about six months. Allow for a stable regimen of other standard of care inhaled therapies.

The most important results showed that compared to placebo, Ohtuvaryre significantly improved lung function, reduced the incidence of pulmonary exacerbations (a period of sudden worsening of lung symptoms), and tended to relieve COPD symptoms. Benefits were observed regardless of patient use of other bronchodilators or individual exacerbation history. Results showed Ohtuvaryre led to significant improvements in lung function after three months compared with placebo, regardless of whether patients had moderate or severe airflow obstruction at the start of the study.

The treatment was also better than placebo at relievingCOPD symptoms, including difficulty breathing, and improving quality of life in both disease severity groups. At several time points, differences between the treatment and placebo groups reached the threshold of statistical significance and/or being considered clinically meaningful.

Ohtuvaryre provides a novel mechanism of action for clinically meaningful improvements in lung function, symptoms and quality of life, regardless of the severity of COPD. Lung function improved significantly in patients taking Ohtuvaryre compared with placebo after three months, regardless of whether the patients were current or former smokers. The treatment also significantly reduced the risk of moderate or severe exacerbation in both groups compared with placebo: 43% in current smokers and 40% in former smokers.

References:https://copdnewstoday.com/news/ohtuvayre-effective-key-patient-subgroups-enhance-trials/